A Look Into GlaxoSmithKline’s Debt
Over the past three months, shares of GlaxoSmithKline (NYSE:GSK) increased by 9.84%. Before we understand the importance of debt, let us look at how much debt GlaxoSmithKline has.
The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy’s Launches Generic Vascepa, Halozyme Strikes Licensing Deal
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 21)
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against…
GSK- Pfizer’s ViiV To Develop ‘Ultra-Long-Acting’ HIV Drugs With $215M Halozyme Deal
GlaxoSmithKline plc (NYSE:GSK), Pfizer Inc (NYSE:PFE), and Shionogi Limited owned ViiV Healthcare has collaborated with Halozyme Therapeutics Inc (NASDAQ:HALO) to gain access to Halozyme’s Enhanze drug delivery…
GlaxoSmithKline CEO Struggling To Get Key Shareholders In Her Favor Amid Pressure From Hedge Fund Activist Elliott Management
GlaxoSmithKline Plc’s (NYSE:GSK) CEO Emma Walmsley struggled to win over key shareholders after Elliott Management attracted converts for radical…
GSK – Vir Biotech’s Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
GlaxoSmithKline plc (NYSE:GSK) and Vir Biotechnology Inc (NASDAQ:VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating sotrovimab in high-risk adult…
GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab
– Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces
hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk
of progression to